BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 32939053)

  • 1. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status.
    Olafsdottir EJ; Borg A; Jensen MB; Gerdes AM; Johansson ALV; Barkardottir RB; Johannsson OT; Ejlertsen B; Sønderstrup IMH; Hovig E; Lænkholm AV; Hansen TVO; Olafsdottir GH; Rossing M; Jonasson JG; Sigurdsson S; Loman N; Nilsson MP; Narod SA; Tryggvadottir L
    Br J Cancer; 2020 Nov; 123(11):1608-1615. PubMed ID: 32939053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.
    Jonasson JG; Stefansson OA; Johannsson OT; Sigurdsson H; Agnarsson BA; Olafsdottir GH; Alexiusdottir KK; Stefansdottir H; Munoz Mitev R; Olafsdottir K; Olafsdottir K; Arason A; Stefansdottir V; Olafsdottir EJ; Barkardottir RB; Eyfjord JE; Narod SA; Tryggvadóttir L
    Br J Cancer; 2016 Sep; 115(7):776-83. PubMed ID: 27537391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
    Tryggvadottir L; Olafsdottir EJ; Olafsdottir GH; Sigurdsson H; Johannsson OT; Bjorgvinsson E; Alexiusdottir K; Stefansson OA; Agnarsson BA; Narod SA; Eyfjord JE; Jonasson JG
    Breast Cancer Res Treat; 2013 Jul; 140(2):375-84. PubMed ID: 23857704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Olopade OI; Eisen A; Lerner-Ellis J; Snyder C; Kim SJ; Sun P; Narod SA
    Br J Cancer; 2019 Feb; 120(4):398-403. PubMed ID: 30723304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.
    Foulkes WD; Metcalfe K; Sun P; Hanna WM; Lynch HT; Ghadirian P; Tung N; Olopade OI; Weber BL; McLennan J; Olivotto IA; Bégin LR; Narod SA
    Clin Cancer Res; 2004 Mar; 10(6):2029-34. PubMed ID: 15041722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival from breast cancer in women with a BRCA2 mutation by treatment.
    Evans DG; Phillips KA; Milne RL; Fruscio R; Cybulski C; Gronwald J; Lubinski J; Huzarski T; Hyder Z; Forde C; Metcalfe K; Senter L; Weitzel J; Tung N; Zakalik D; Ekholm M; Sun P; Narod SA;
    Br J Cancer; 2021 Apr; 124(9):1524-1532. PubMed ID: 33597716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
    Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
    Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
    Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
    Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
    Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.
    Karp SE; Tonin PN; Bégin LR; Martinez JJ; Zhang JC; Pollak MN; Foulkes WD
    Cancer; 1997 Aug; 80(3):435-41. PubMed ID: 9241077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
    Sopik V; Sun P; Narod SA
    Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
    Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
    J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
    Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
    Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF
    BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.